Overcoming blood shortages: red blood cell and platelet substitutes and membrane modifications.
D000818:Animals; D001241:Aspirin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D001782:Blood Donors / Q000600:supply & distribution*; D001792:Blood Platelets / Q000737:chemistry; D001793:Blood Preservation; D001802:Blood Substitutes; D001803:Blood Transfusion / Q000706:statistics & numerical data*; D002417:Cattle; D002986:Clinical Trials as Topic; D003432:Cross-Linking Reagents / Q000494:pharmacology; D015925:Cryopreservation; D004338:Drug Combinations; D004910:Erythrocyte Membrane / Q000187:drug effects; D005466:Fluorocarbons / Q000627:therapeutic use; D006026:Glycoside Hydrolases / Q000494:pharmacology; D006454:Hemoglobins / Q000009:adverse effects / Q000737:chemistry / Q000187:drug effects / Q000627:therapeutic use; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives
D001802:Blood Substitutes; D003432:Cross-Linking Reagents; D004338:Drug Combinations; D005466:Fluorocarbons; D006454:Hemoglobins; D006895:Hydroxyethyl Starch Derivatives; C053936:hemoglobin XL99alpha; C037158:polyhemoglobin; C021630:bis(3,5-dibromosalicyl)fumarate; C017323:glucose, glycerol, hydroxyethyl starch, perfluorodecalin, perfluorotripropylamine, pluronic F-68, salts, yolk phospholipids drug combination; D006026:Glycoside Hydrolases; D001241:Aspirin